Disopyramide: Although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 3, 2006, Pages 421-423

  Dumaine, R ^a   Antzelevitch, C ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CYTOCHROME P450 INHIBITOR; DISOPYRAMIDE; DOFETILIDE; ERYTHROMYCIN; GREPAFLOXACIN; KETOCONAZOLE; MACROLIDE; POTASSIUM CHANNEL HERG; QUINIDINE; SERTINDOLE; SOTALOL; TERFENADINE;

DRUG ACTIVITY; DRUG EFFECT; DRUG FATALITY; DRUG INDICATION; EDITORIAL; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; SHORT QT SYNDROME; SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DISOPYRAMIDE; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; LONG QT SYNDROME; MUTATION; RISK FACTORS; SYNDROME;

EID: 33748432244     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.06.070     Document Type: Editorial

References (26)

1. Dumaine R., Roy M.L., and Brown A.M. Blockade of HERG and Kv1.5 by ketoconazole. J. Pharmacol. Exp. Ther. 286 2 (1998 (Aug.)) 727-735
2. Roy M.L., Dumaine R., and Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94 (1996) 817-823
3. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. J. Intern. Med. 259 1 (2006 (Jan.)) 59-69
4. Malik M., and Camm A.J. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 24 5 (2001) 323-351
5. Witchel H.J., and Hancox J.C. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. Physiol. 27 10 (2000 (Oct.)) 753-766
6. Kurita T., Ohe T., Shimizu W., Suyama K., Takaki H., Aihara N., et al. Early afterdepolarization like activity in patients with class IA induced long QT syndrome and torsade de pointes. PACE 20 (1997) 695-705
7. Paul A.A., Witchel H.J., and Hancox J.C. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun. 280 5 (2001 (Feb. 9)) 1243-1250
8. McPate M.J., Duncan R.S., Witchel H.J., and Hancock J.C. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. J. Mol. Cell Cardiol. 41 3 (2006) 563-566
9. Gussak I., Brugada P., Brugada J., Wright R.S., Kopecky S.L., Chaitman B.R., et al. Idiopathic short QT interval: a new clinical syndrome?. Cardiology 94 2 (2000) 99-102
10. Gaita F., Giustetto C., Bianchi F., Wolpert C., Schimpf R., Riccardi R., et al. Short QT Syndrome: a familial cause of sudden death. Circulation 108 8 (2003 (Aug. 26)) 965-970
11. Giustetto C., Wolpert C., Anttonen O.M., Sbragia P., Leone G., Schimp F.R., et al. Clinical presentation of the patients with short QT syndrome. Heart Rhythm 2 (2006) S61 [Ref Type: Abstract]
12. Antzelevitch C., and Francis J. Congenital short QT syndrome. Indian Pacing and Electrophysiology Journal 4 (2004) 46-49
13. Bjerregaard P., Jahangir A., and Gussak I. Targeted therapy for short QT syndrome. Expert Opin. Ther. Targets 10 3 (2006 (Jun.)) 393-400
14. Fujiki A., Sugao M., Nishida K., Sakabe M., Tsuneda T., Mizumaki K., et al. Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships. J. Cardiovasc. Electrophysiol. 15 1 (2004 (Jan.)) 59-63
15. Viskin S., Zeltsner D., Ish-Shalom M., Katz A., Glikson M., Justo D., et al. Is idiopathic ventricular fibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricular fibrillation and healthy controls. Heart Rhythm 1 5 (2004) 587-591
16. Extramiana F., and Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 110 (2004) 3661-3666
17. Kr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc. Res. 67 3 (2005) 498-509
18. Brugada R., Hong K., Dumaine R., Cordeiro J., Gaita F., Borggrefe M., et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109 1 (2004 (Jan. 6)) 30-35
19. Hong K., Bjerregaard P., Gussak I., and Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. 16 4 (2005 (Apr.)) 394-396
20. Kr potassium channel. Cell 81 (1995) 299-307
21. Bellocq C., Van Ginneken A.C., Bezzina C.R., Alders M., Escande D., Mannens M.M., et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109 20 (2004 (May 25)) 2394-2397
22. Priori S.G., Pandit S.V., Rivolta I., Berenfeld O., Ronchetti E., Dhamoon A., et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ. Res. 96 (2005 (Mar. 10)) 800-807
23. Gaita F., Giustetto C., Bianchi F., Schimpf R., Haissaguerre M., Calo L., et al. Short QT syndrome: pharmacological treatment. J. Am. Coll. Cardiol. 43 8 (2004 (Apr. 21)) 1494-1499
24. Wolpert C., Schimpf R., Giustetto C., Antzelevitch C., Cordeiro J., Dumaine R., et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J. Cardiovasc. Electrophysiol. 16 1 (2005 (Jan.)) 54-58
25. Wolpert C., Schimpf R., Veltmann C., Giustetto C., Gaita F., and Borggrefe M. Clinical characteristics and treatment of short QT syndrome. Expert. Rev. Cardiovasc. Ther. 3 4 (2005 (Jul. 1)) 611-617
26. Schimpf R., Wolpert C., Bianchi F., Giustetto C., Gaita F., Bauersfeld U., et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J. Cardiovasc. Electrophysiol. 14 12 (2003 Dec.) 1273-1277